Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Higher incidence of co-expression of BCR-ABL fusion transcripts in an Eastern Indian population

View through CrossRef
Abstract Background Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, caused by a balanced reciprocal translocation (t(9;22) (q34;q11)) that leads to the formation of BCR (Breakpoint Cluster Region)-ABL (Abelson) fusion transcripts known as Philadelphia (Ph) chromosome. The prevalence of BCR-ABL fusion transcripts in Indian CML population is poorly understood, and few studies have been reported from India. The aim of the present study was to determine the frequencies as well as prognostic effects of the three fusion transcripts, i.e. b2a2, b3a2 and e1a2 in an Indian population. Methods RNA was isolated from total 123 samples, 27 bone marrow (BM) samples and 96 peripheral blood (PB) samples, of CML patient followed by cDNA synthesis. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using TaqMan® assay (ABI, CA, USA) to monitor BCR-ABL transcript. Results Ph' chromosome was observed in 103 patients whereas it was not detected in 20 cases. qRT-PCR revealed that the b3a2 fusion transcripts were the most common transcript in CML patients (63.41%) while b2a2 fusion transcript was present in 16.26% cases. Co-expression of b3a2 + b2a2 fusion transcript was observed in 0.81% cases whereas co-expression of b3a2 + e1a2 fusion transcript was found in 1.63% cases. There was no correlation observed between b3a2 fusion transcript and platelet count. The fusion transcript b2a2 was observed in relatively younger patients compared to b3a2 fusion transcript. Although this correlation was not statistically significant. Conclusion The co-expression of BCR-ABL fusion transcripts was higher (63.41% aggregate of b3a2) in the present population in contrast with other populations reported. This finding was consistent with the frequency data reported from Sudan.
Title: Higher incidence of co-expression of BCR-ABL fusion transcripts in an Eastern Indian population
Description:
Abstract Background Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, caused by a balanced reciprocal translocation (t(9;22) (q34;q11)) that leads to the formation of BCR (Breakpoint Cluster Region)-ABL (Abelson) fusion transcripts known as Philadelphia (Ph) chromosome.
The prevalence of BCR-ABL fusion transcripts in Indian CML population is poorly understood, and few studies have been reported from India.
The aim of the present study was to determine the frequencies as well as prognostic effects of the three fusion transcripts, i.
e.
b2a2, b3a2 and e1a2 in an Indian population.
Methods RNA was isolated from total 123 samples, 27 bone marrow (BM) samples and 96 peripheral blood (PB) samples, of CML patient followed by cDNA synthesis.
Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using TaqMan® assay (ABI, CA, USA) to monitor BCR-ABL transcript.
Results Ph' chromosome was observed in 103 patients whereas it was not detected in 20 cases.
qRT-PCR revealed that the b3a2 fusion transcripts were the most common transcript in CML patients (63.
41%) while b2a2 fusion transcript was present in 16.
26% cases.
Co-expression of b3a2 + b2a2 fusion transcript was observed in 0.
81% cases whereas co-expression of b3a2 + e1a2 fusion transcript was found in 1.
63% cases.
There was no correlation observed between b3a2 fusion transcript and platelet count.
The fusion transcript b2a2 was observed in relatively younger patients compared to b3a2 fusion transcript.
Although this correlation was not statistically significant.
Conclusion The co-expression of BCR-ABL fusion transcripts was higher (63.
41% aggregate of b3a2) in the present population in contrast with other populations reported.
This finding was consistent with the frequency data reported from Sudan.

Related Results

TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL
Chronic myeloid leukemia (CML) is a hematopoietic malignancy caused by the BCR-ABL fusion gene. Although tyrosine kinase inhibitors (TKIs) targeting the oncoprotein BCR-ABL have dr...
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
PARP Inhibition Sensitize BCR-ABL1 Positive Cel
Introduction: BCR-ABL1 play a key role in the development of chronic myelogenous leukemia and a part of Ph1 positive acute lymphoblastic leukemia (ALL). BCR-ABL1 fun...
Higher Incidence of Co-Expression of BCR-ABL Fusion Transcripts in an Eastern Indian Population
Higher Incidence of Co-Expression of BCR-ABL Fusion Transcripts in an Eastern Indian Population
Abstract Background Chronic myeloid leukaemia (CML) is a hematopoietic stem cell disorder, caused by a balanced reciprocal translocation (t(9;22) (q34;q11))that lead to th...
Preliminary Functional Studies of hnRNPK in Progression of CML
Preliminary Functional Studies of hnRNPK in Progression of CML
Abstract The blast crisis(BC) is terminal phase of chronic myeloid leukemia (CML), which is accompanied by an increase in both BCR/ABL mRNA and protein level and ima...
RETRACTED ARTICLE: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia
RETRACTED ARTICLE: MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia
AbstractAccumulating evidences demonstrated that the induction of epithelial-mesenchymal transition (EMT) and aberrant expression of microRNAs (miRNAs) are associated with tumorige...
The Nuclear Fusion Award
The Nuclear Fusion Award
The Nuclear Fusion Award ceremony for 2009 and 2010 award winners was held during the 23rd IAEA Fusion Energy Conference in Daejeon. This time, both 2009 and 2010 award winners w...

Back to Top